Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
Authors:
- Andrew Lee HongAHAndrew Lee Hong
- Yuen-Yi TsengYTYuen-Yi Tseng
- Jeremiah Anthony WalaJWJeremiah Anthony Wala
- Won Jun KimWKWon Jun Kim
- Bryan D. KynnapBKBryan D. Kynnap
- Mihir B. DoshiMDMihir B. Doshi
- Guillaume KugenerGKGuillaume Kugener
- Gabriel J. SandovalGSGabriel J. Sandoval
- Thomas P. HowardTHThomas P. Howard
- Ji LiJLJi Li
- Xiaoping YangXYXiaoping Yang
- Michelle TillgrenMTMichelle Tillgren
Preprint
Abstract
Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. Through direct-to-patient outreach, we developed genomically faithful patient-derived models of RMC. Using whole genome sequencing, we identified intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele, confirming that SMARCB1 loss occurs in RMC. Biochemical and functional characterization of these RMC models revealed that RMC depends on the loss of SMARCB1 for survival and functionally resemble other cancers that harbor loss of SMARCB1 , such as malignant rhabdoid tumors or atypical teratoid rhabdoid tumors. We performed RNAi and CRISPR-Cas9 loss of function genetic screens and a small-molecule screen and identified UBE2C as an essential gene in SMARCB1 deficient cancers. We found that the ubiquitin-proteasome pathway was essential for the survival of SMARCB1 deficient cancers in vitro and in vivo. Genetic or pharmacologic inhibition of this pathway leads to G2/M arrest due to constitutive accumulation of cyclin B1. These observations identify a synthetic lethal relationship that may serve as a therapeutic approach for patients with SMARCB1 deficient cancers.Keywords
All Related Versions
- Published version: eLife, 8.
This publication has 77 references indexed in Scilit:
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012
- APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1Nature Cell Biology, 2012
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Bortezomib Stabilizes Mitotic Cyclins and Prevents Cell Cycle Progression via Inhibition of UBE2C in Colorectal CarcinomaThe American Journal of Pathology, 2011
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005